Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1708 - Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: a phase II pilot study

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Prostate Cancer

Presenters

Michael Mark

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

M. Mark1, D. Klingbiel2, U. Mey1, R. Winterhalder3, C. Rothermundt4, S. Gillessen4, R. von moos1, G. Manetsch1, R. Cathomas1

Author affiliations

  • 1 Hämatologie/onkologie, Kantonsspital Graubünden, 7000 - Chur/CH
  • 2 Coordinating Center, SAKK, 3000 - berne/CH
  • 3 Onkologie, Luzerner Kantonsspital, 6004 - Luzern/CH
  • 4 Onkologie, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
More

Resources

Abstract 1708

Background

Abi has become one of the standard 1st line treatments in mCRPC. Cross-talk signalling pathways such as PI3K/Akt/mTOR represent a possible resistance mechanism against Abi. The oral antidiabetic agent Met has been shown to have antiproliferative effects via inhibiting mTOR. We hypothesized that the addition of Met to pts with PSA progression on Abi could influence resistance to Abi and thus delaying start of second line therapy.

Methods

Men with mCRPC experiencing PSA progression on first line Abi were enrolled in this prospective single-arm open-label multicentre Phase II trial. Pts with visceral metastases were excluded. Abi (1000mg qd)/Prednisone (5mg bd) treatment was continued and pts received Met 1000mg bd in addition. Primary endpoint was progression-free survival (PFS) at 12 weeks according to RECIST 1.1 or PCWG2 criteria. Secondary endpoints included PFS, PSA response rate, OS, toxicity and safety. 25 pts were planned to consider the trial uninteresting (H0: PFS at 12 weeks ≤ 15%) or promising (H1: ≥ 35%) using a 5% significance level and a 80% power.

Results

25 pts with a median age of 76 years (IQR 72-82), were included between November 2013-September 2016 in 3 Swiss cancer centres. Median time to development of castration resistance was 19.5 months (mts) (IQR 11-24), and median duration on Abi before study entry was 12.1 mts (IQR 8-19). PFS rate at 12 weeks was 12% (3 of 25 pts), median PFS was 9 weeks (IQR 7-11) and median OS 20.7 mts (IQR 14-23). One patient had PSA decline of 30% and another one of 26%, all other had PSA progression. 4 pts (16%) had radiographic progression at week 12. 11 pts (44%) had grade 1 and two pts each grade 2 (8%) or grade 3 (8%) gastrointestinal toxicity (nausea, diarrhoea).

Conclusions

The addition of Met to Abi in pts with mCRPC after PSA progression on Abi did not have a substantial impact on PFS or PSA response. Toxicity of Met in combination with Abi was higher than expected.

Clinical trial identification

NCT01677897

Legal entity responsible for the study

Michael Mark

Funding

Janssen

Disclosure

S. Gillessen, R. Cathomas: Advisor for the Janssen on advisory boards. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.